SCHEMBL2708089

SCHEMBL2708089

On1c(-c2ccccc2)nc2cnc3ccccc3c21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 4/20 0.48
KDM4E B2RXH2 6/20 0.45
KMT2A Q03164 6/20 0.45
MEN1 O00255 4/20 0.45
HTT P42858 4/20 0.45
LMNA P02545 3/20 0.45
ATM Q13315 2/20 0.45
ADORA3 P0DMS8 1/20 0.44
ADORA1 P30542 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
CYP1A2 P05177 1/20 0.43
GAA P10253 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9218314 0.81 TLR7 (0.62) TLR7KDM4EKMT2AMEN1ATM
SCHEMBL2682715 0.81 KDM4E (0.43) TLR7KDM4EKMT2AMEN1LMNA
SCHEMBL3872025 0.79 KDM4E (0.44) TLR7KDM4EADORA3CYP1A2GAA
SCHEMBL2707491 0.78 TLR7 (0.48) TLR7KDM4EKMT2AADORA3ADORA1
SCHEMBL10739564 0.77 ALDH1A1 (0.64) TLR7KDM4EKMT2AMEN1LMNA
SCHEMBL2707466 0.75 TLR7 (0.45) TLR7KDM4EKMT2AHTTADORA3
SCHEMBL2707187 0.74 TLR7 (0.50) TLR7KMT2ALMNAADORA3ADORA1
SCHEMBL2682714 0.74 KDM4E (0.42) TLR7KDM4EKMT2AMEN1LMNA
SCHEMBL2708212 0.74 KMT2A (0.52) TLR7KDM4EKMT2AMEN1LMNA
SCHEMBL28161209 0.72 POLB (0.48) KDM4EKMT2AMEN1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1789042-B1 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2012-05-02 EP disclosed
US-7579359-B2 1-alkoxy 1H-imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-08-25 US disclosed
EP-1789042-A4 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2009-07-22 EP disclosed
US-20090005376-A1 imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2009-01-01 US disclosed
EP-1789042-A2 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-30 EP disclosed
WO-2006028962-A2 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005376-A1 imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases IL2, IL4, IRF3 TLR7 110/4885KDM4E 2441/4885KMT2A 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.